Pegavision Corp
TWSE:6491
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
367
532
|
| Price Target |
|
We'll email you a reminder when the closing price reaches TWD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Pegavision Corp
Additional Paid In Capital
Pegavision Corp
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Pegavision Corp
TWSE:6491
|
Additional Paid In Capital
NT$4.3B
|
CAGR 3-Years
33%
|
CAGR 5-Years
78%
|
CAGR 10-Years
N/A
|
|
|
M
|
Medtecs International Corporation Ltd
SGX:546
|
Additional Paid In Capital
$4.7m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
|
V
|
Visco Vision Inc
TWSE:6782
|
Additional Paid In Capital
NT$1.4B
|
CAGR 3-Years
235%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
SciVision Biotech Inc
TWSE:1786
|
Additional Paid In Capital
NT$841.6m
|
CAGR 3-Years
10%
|
CAGR 5-Years
6%
|
CAGR 10-Years
5%
|
|
|
OK Biotech Co Ltd
TWSE:4155
|
Additional Paid In Capital
NT$890.5m
|
CAGR 3-Years
16%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
Pegavision Corp
Glance View
Pegavision Corp. focusing on research, development, manufacture and marketing of soft contact lenses and the medical optic devices. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2014-12-30. The firm distributes its products within domestic market and to overseas markets.
See Also
What is Pegavision Corp's Additional Paid In Capital?
Additional Paid In Capital
4.3B
TWD
Based on the financial report for Jun 30, 2024, Pegavision Corp's Additional Paid In Capital amounts to 4.3B TWD.
What is Pegavision Corp's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
78%
Over the last year, the Additional Paid In Capital growth was 136%. The average annual Additional Paid In Capital growth rates for Pegavision Corp have been 33% over the past three years , 78% over the past five years .
You don't have any saved screeners yet
